[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

ResMed Inc. (RMD) – Form 4 insider transaction: Director and Chairman emeritus Peter C. Farrell disclosed the sale of 945 common shares on 07/02/2025 at an average price of $255.49 per share. The trade, executed under a previously adopted Rule 10b5-1 trading plan dated May 28 2024, reduced Farrell’s direct holdings to 68,273 shares. No derivative securities were involved, and no additional transactions were reported.

The disposition represents roughly 1.4% of the insider’s pre-transaction stake and does not change his board status. Because the sale was pre-planned, it typically signals liquidity management rather than an active valuation call.

Positive

• Large residual stake: Farrell still holds 68,273 shares, maintaining strong alignment with shareholders.
• Trade executed under Rule 10b5-1, supporting transparency and reducing insider-information risk.

Negative

• Insider sale of 945 shares at $255.49, a modest but directional disposition.

Insights

Securities Analyst

TL;DR – Modest, pre-planned insider sale; limited market impact.

The Form 4 shows a single sale of 945 shares (~$0.24 million) by long-time director Peter Farrell. Post-sale ownership remains robust at 68,273 shares, indicating continued alignment with shareholders. Given the 10b5-1 framework, motives are likely personal diversification. The transaction size is immaterial relative to daily volume and the insider’s total stake, so I view the filing as neutral for valuation or sentiment.

Corporate Governance Expert

TL;DR – Governance-friendly disclosure; pre-scheduled trade limits concern.

From a governance angle, the use of a Rule 10b5-1 plan enhances transparency and mitigates potential misuse of non-public information. The board chair emeritus retains significant equity, preserving incentive alignment. No red flags such as large percentage divestitures, option exercises, or group filings are present. Therefore, the filing bears no adverse governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	07/02/2025		S(1)		945	D	$255.49	68,273	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted May 28, 2024

	Peter C. Farrell, Chairman emeritus	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ResMed (RMD) shares did Peter C. Farrell sell?

The Form 4 reports a sale of 945 common shares.

What price did the insider receive for the RMD shares?

The shares were sold at an average price of $255.49 each.

How many ResMed shares does the insider still own after the sale?

Peter Farrell directly owns 68,273 shares following the transaction.

Was the sale conducted under a pre-arranged trading plan?

Yes. The transaction was executed under a Rule 10b5-1 plan adopted on May 28 2024.

Does this filing include any derivative security transactions?

No. No derivative securities were acquired or disposed of in this Form 4.